Home / Business and Economy / BioLife Unveils Oral Peptide Delivery Breakthrough
BioLife Unveils Oral Peptide Delivery Breakthrough
3 Nov
Summary
- Patented oral peptide delivery technology protects peptides in the GI tract.
- Preclinical studies show oral semaglutide delivery success.
- Patents secured in US and France, valid until 2042.
BioLife Products Limited will present its innovative oral peptide delivery technology and advancements in its intellectual property portfolio at the LSX Investival Showcase on November 16, 2026, in London. This technology aims to revolutionize the delivery of peptide therapeutics.
The company's patented effervescent tablet system is designed to protect peptides during gastrointestinal transit and facilitate systemic delivery. This approach builds upon over 35 years of effervescence expertise and 20 years of oral peptide research.
Recent preclinical studies have confirmed measurable systemic exposure of semaglutide following oral administration. This in vivo proof of concept, combined with earlier human trials of oral insulin, supports further investigation into other peptide medicines.
BioLife holds granted patents in the United States and France, with international filings in progress. The U.S. patent provides protection for multiple GLP-1 receptor agonists, including semaglutide, extending until 2042.
